Plus100 is founded by Arnold Willemsen in 2012. Mr. Willemsen holds a master of science degree in mathematical engineering obtained at Delft University of Technology. He has specialized himself in applied statistics. He further holds a CStat professional award obtained at the Netherlands Statistical Society. He has twenty years of experience in statistics. He has worked for four of the top seven pharmaceutical companies by largest sales, and several key biotech companies. He has advised them and their partnering companies on drug development programs in almost all phases. Prior to being appointed ceo at Plus100, he held global responsibility for Aldurazyme®, enzyme replacement therapy for Mucopolysaccharidosis I, and Prochymal®, the world’s first approved stem cell drug.